Skip to main content

Table 1 Demographic and baseline characteristics of the diabetes, CKD, and chronic CVD subgroups (randomized set)

From: Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study

 

Diabetes (n=387)

CKD (n=103)

Chronic CVD (n=227)

 

OM 40/ AML 10 mg

OM 40/ HCTZ 25 mg

AML 10/ HCTZ 25 mg

OM 40/ AML 10/ HCTZ 25 mg

OM 40/ AML 10 mg

OM 40/ HCTZ 25 mg

AML 10/ HCTZ 25 mg

OM 40/ AML 10/ HCTZ 25 mg

OM 40/ AML 10 mg

OM 40/ HCTZ 25 mg

AML 10/ HCTZ 25 mg

OM 40/ AML 10/ HCTZ 25 mg

 

(n=100)

(n=99)

(n=92)

(n=96)

(n=29)

(n=25)

(n=29)

(n=20)

(n=56)

(n=61)

(n=55)

(n=55)

Age, mean (SD), yrs

59.7 (8.9)

60.3 (8.7)

56.5 (9.4)

58.1 (9.4)

71.0 (7.8)

71.5 (9.4)

69.4 (9.5)

68.1 (10.0)

60.2 (11.2)

61.1 (9.8)

58.2 (11.0)

58.6 (10.9)

Male, n (%)

60 (60.0)

54 (54.5)

52 (56.5)

51 (53.1)

9 (31.0)

10 (40.0)

10 (34.5)

5 (25.0)

40 (71.4)

38 (62.3)

34 (61.8)

39 (70.9)

Ethnicity

 

Hispanic/Latino, n (%)

21 (21.0)

18 (18.2)

13 (14.1)

15 (15.6)

1 (3.4)

2 (8.0)

3 (10.3)

2 (10.0)

8 (14.3)

5 (8.2)

7 (12.7)

8 (14.5)

Race

 

White, n (%)

72 (72.0)

73 (73.7)

58 (63.0)

67 (69.8)

18 (62.1)

19 (76.0)

21 (72.4)

13 (65.0)

40 (71.4)

45 (73.8)

37 (67.3)

35 (63.6)

Black, n (%)

26 (26.0)

24 (24.2)

29 (31.5)

25 (26.0)

9 (31.0)

5 (20.0)

7 (24.1)

6 (30.0)

16 (28.6)

16 (26.2)

18 (32.7)

17 (30.9)

Obesity, n (%)*

77 (77.0)

74 (74.7)

71 (77.2)

73 (76.0)

9 (31.0)

2 (8.0)

7 (24.1)

6 (30.0)

32 (57.1)

40 (65.6)

35 (63.6)

33 (60.0)

Hypertension duration, mean (SD), y

12.8 (9.6)

13.2 (10.5)

11.2 (9.6)

10.7 (9.8)

12.1 (8.0)

14.0 (10.0)

13.0 (9.3)

14.8 (14.4)

12.0 (8.0)

15.0 (12.3)

12.9 (9.9)

13.3 (11.0)

Baseline BP, mean (SD), mm Hg

172.2/98.6 (13.5/7.5)

173.1/97.8 (14.7/7.6)

170.7/99.3 (13.6/6.7)

170.7/98.3 (16.0/6.9)

174.4/96.4 (12.5/8.8)

172.2/96.0 (11.6/7.6)

172.9/97.4 (17.1/6.6)

173.8/96.6 (16.5/6.5)

173.4/101.0 (16.2/10.6)

172.8/99.3 (11.7/9.3)

174.2/100.8 (16.7/7.1)

171.7/100.4 (11.0/9.1)

  1. *BMI ≥30 kg/m2.
  2. AML, amlodipine; BMI, body mass index; CKD, chronic kidney disease; CVD, cardiovascular disease; HCTZ, hydrochlorothiazide; OM, olmesartan medoxomil; SD, standard deviation.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840